611 related articles for article (PubMed ID: 17428847)
21. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
22. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
Dang Y; Wang X; Zhou T; York IA; Zheng YH
J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of Alu retrotransposition by APOBEC3G.
Hulme AE; Bogerd HP; Cullen BR; Moran JV
Gene; 2007 Apr; 390(1-2):199-205. PubMed ID: 17079095
[TBL] [Abstract][Full Text] [Related]
25. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
Kaiser SM; Emerman M
J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
[TBL] [Abstract][Full Text] [Related]
26. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
[TBL] [Abstract][Full Text] [Related]
28. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
29. Stably expressed APOBEC3F has negligible antiviral activity.
Miyagi E; Brown CR; Opi S; Khan M; Goila-Gaur R; Kao S; Walker RC; Hirsch V; Strebel K
J Virol; 2010 Nov; 84(21):11067-75. PubMed ID: 20702622
[TBL] [Abstract][Full Text] [Related]
30. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
Chaipan C; Smith JL; Hu WS; Pathak VK
J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
[TBL] [Abstract][Full Text] [Related]
31. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
Wichroski MJ; Robb GB; Rana TM
PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
[TBL] [Abstract][Full Text] [Related]
32. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3 inhibits mouse mammary tumour virus replication in vivo.
Okeoma CM; Lovsin N; Peterlin BM; Ross SR
Nature; 2007 Feb; 445(7130):927-30. PubMed ID: 17259974
[TBL] [Abstract][Full Text] [Related]
34. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
35. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
Yang B; Chen K; Zhang C; Huang S; Zhang H
J Biol Chem; 2007 Apr; 282(16):11667-75. PubMed ID: 17272283
[TBL] [Abstract][Full Text] [Related]
36. Multifaceted antiviral actions of APOBEC3 cytidine deaminases.
Chiu YL; Greene WC
Trends Immunol; 2006 Jun; 27(6):291-7. PubMed ID: 16678488
[TBL] [Abstract][Full Text] [Related]
37. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
38. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
[TBL] [Abstract][Full Text] [Related]
39. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
[TBL] [Abstract][Full Text] [Related]
40. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
Soros VB; Yonemoto W; Greene WC
PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]